Published in Scientifica (Cairo) on September 17, 2012
DULCIS (D-dimer and ULtrasonography in Combination Italian Study) (DULCIS) | NCT00954395
Long-term prognosis and related factors towards patients with acute pulmonary thromboembolism. Int J Clin Exp Med (2015) 0.77
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med (1995) 8.08
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med (1991) 7.62
The risk of recurrent venous thromboembolism in men and women. N Engl J Med (2004) 7.41
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med (2006) 6.62
Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation (2005) 5.38
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med (2004) 4.38
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Natural history of venous thromboembolism. Circulation (2003) 3.67
Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet (1992) 3.60
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
D-dimer levels and risk of recurrent venous thromboembolism. JAMA (2003) 3.30
Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA (2005) 3.27
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med (2003) 3.18
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med (2000) 2.86
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (2003) 2.81
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med (2008) 2.51
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica (2008) 2.46
Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost (2002) 2.44
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med (2003) 2.28
A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med (1992) 2.27
Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med (2000) 2.12
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation (2010) 2.05
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica (2007) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost (2009) 1.92
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med (2008) 1.91
The epidemiology of venous thromboembolism in the community. Thromb Haemost (2001) 1.86
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med (2010) 1.83
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med (2000) 1.81
Clinical guidelines for testing for heritable thrombophilia. Br J Haematol (2010) 1.79
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA (2006) 1.72
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis (2009) 1.71
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med (2001) 1.70
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med (2010) 1.68
Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA (1998) 1.67
High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost (2009) 1.64
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med (1997) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost (2006) 1.58
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med (1997) 1.53
Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med (2008) 1.52
Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood (2008) 1.51
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation (2010) 1.50
Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes. J Thromb Haemost (2007) 1.48
Death due to recurrent thromboembolism among younger healthier individuals hospitalized for idiopathic pulmonary embolism. Thromb Haemost (2008) 1.47
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med (1996) 1.45
Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost (1995) 1.44
The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost (2003) 1.42
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost (2008) 1.39
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med (2006) 1.34
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost (2009) 1.34
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med (2010) 1.27
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med (2000) 1.24
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood (2011) 1.14
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation (2003) 1.13
Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. J Vasc Surg (2001) 1.13
New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost (2006) 1.12
Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. J Vasc Surg (1995) 1.11
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost (2012) 1.11
Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med (2004) 1.09
Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis (2007) 1.08
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood (2004) 1.06
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost (2010) 1.06
Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost (2005) 1.06
Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost (2006) 1.06
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost (2012) 1.06
Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica (2002) 1.04